ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Advances in single cell omics applications in mantle cell lymphoma].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm characterized by marked biological and clinical heterogeneity. Although novel strategies such as Bruton's tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy have improved outcomes for a subset of patients, primary resistance, early relapse, and post-treatment progression remain major challenges in clinical management. Conventional bulk-level assays have limited capacity to resolve subclonal architecture, cellular state transitions, and microenvironmental remodeling of MCL. The development of single-cell omics and its derived spatially resolved technologies now enables the profiling of clonal evolution, immune ecology, and resistance-associated programs of MCL at both cellular and spatial dimensions. This review summarizes recent advances in the application of single-cell RNA sequencing, single-cell B/T-cell receptor sequencing, single-cell DNA sequencing, single-cell epigenomics, multimodal profiling, and spatial transcriptomic/imaging approaches to MCL. We focus on their contributions to the understanding of intratumoral heterogeneity, immune microenvironmental remodeling, therapeutic resistance, and potential clinical translation, as well as current challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.